Showing results (351-360 of 722) with videos related to
Sort By:
Pageof 73
The Lancet. Haematology|June 4, 2026
Prediction of bone marrow fibrosis from complete blood count in myeloproliferative neoplasms (FIBOM-AI): a multicentre machine learning model development and validation studyMarie Donzel, Syrine Khedimallah, Sabrina Barriere, et al.The Lancet. Haematology|June 12, 2026
Real-world patient-reported symptomatic adverse events and concordance with physician assessments after CAR T-cell therapy in patients with aggressive B-cell lymphomas: a prospective studyFabio Efficace, Pier Luigi Zinzani, Francesca Bonifazi, et al.The Lancet. Haematology|June 15, 2026
Inotuzumab ozogamicin in paediatric very high risk first B-cell acute lymphoblastic leukaemia relapse (ITCC-059): a multicentre, single-arm, phase 2 trialNicolò Peccatori, Franco Locatelli, Anneke C J Ammerlaan, et al.The Lancet. Haematology|July 30, 2026
Haematopoietic cell transplantation for relapsed or refractory classical Hodgkin lymphoma: a retrospective, registry-based cohort study of 19 498 patients from the EBMT Lymphoma Working GroupAli Bazarbachi, Mathilde Fekom, Carmen Martinez, et al.The Lancet. Haematology|August 21, 2026
Redefining plasma cell leukaemiaS Vincent Rajkumar, Shaji KumarThe Lancet. Haematology|August 27, 2026
Venetoclax added to dose-adjusted EPOCH-R for newly diagnosed double-hit lymphomas: phase 2 results from ALLIANCE A051701, an open-label, randomised, controlled, phase 2-3 trialJeremy S Abramson, Susan Geyer, Sharmila Giri, et al.The Lancet. Haematology|August 27, 2026
CD19 CAR T-cell therapy (GLPG5101) for relapsed or refractory B-cell non-Hodgkin lymphoma (ATALANTA-1): phase 1 results from a single-arm, multicentre, phase 1/2 studyMarie José Kersten, Maria T Kuipers, Pim G N J Mutsaers, et al.The Lancet. Haematology|August 27, 2026
Beyond maximum grade: the role of real-world digital health technologies to capture, predict, and manage treatment toxicity in haematological cancersTarec Christoffer El-Galaly, Irène Buvat, Raul Córdoba, et al.The Lancet. Haematology|September 16, 2026
Topical ruxolitinib for chronic cutaneous graft-versus-host disease: a single-centre, randomised, double-blind, intra-patient-controlled phase 2 trialAlina Markova, Jelena Ostojić, Veronica Rotemberg, et al.The Lancet. Haematology|June 30, 2022
Choosing between intensive and less intensive front-line treatment approaches for older patients with newly diagnosed acute myeloid leukaemiaNicholas J Short, Hagop KantarjianPageof 73